Pharma APMs: Can the industry learn to play well with others?

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Maggie Alston, Bruce S. Pyenson | 05 September 2018

Pharmaceutical manufacturers and insurers may embrace alternative payment models (APMs) as a payment mechanism in some situations. The dynamics of APMs suggest a potential win for insurers, pharmaceutical manufacturers, and patients through an emphasis on reducing cost and improving outcomes.

This article was originally published by Managed Care.

Read or print the article

Authors

Featured topics